Skip to main content

Sunny Malhotra Sareen

I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Sunny Malhotra Sareen

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute.

As the Principal Investigator, I have a strong commitment to Translational Research and a solid background in biomedical sciences. My expertise lies in the discovery of biomarkers through genetic indicators and gene expression, particularly in identifying new therapeutic targets for neurological diseases. Additionally, I have over a decade of involvement in pharmacogenetics, genomics, and inflammasome biology studies.

I have received training from various institutions, including the National Institute of Immunology (New Delhi), the Institute of Genomics and Integrative Biology (New Delhi), Progenika Biopharma, and UKE Hamburg.

Dr. Malhotra has developed research lines funded by the Carlos III Health Institute during the periods 2017-2019 and 2021-2024.

Selected awards/grants granted to the PI include:

"Novartis Award" for the best oral communication;
"Extraordinary Award" of the year for his "Doctorate" (UPF);
"Merck Solidarity Award" for multiple sclerosis of the year;
"Hope Award" for multiple sclerosis of the year;
"Marie Curie Fellowship": as a predoctoral researcher;
"Educational Fellowship": from ECTRIMS (Boston);
"PERIS Fellowship": as a postdoctoral researcher.
I serve as a lecturer and have extensive experience reviewing research articles in international journals. I am a member of various scientific editorial committees and have supervised master's and doctoral theses with 'Cum Laude' honors.

I am a member of the Human Resources Strategy for Researchers (HRS4R) Committee at the center, with the main motto of promoting excellence in science in Europe.

In general, my primary research focus includes neuroinflammatory/neurodegenerative diseases and the search for new biomarkers/therapeutic target objectives and drug discovery.

Projects

SGR-Cat 2021: Neuroimmunologia Clínica

IP: Montalban Gairín, Xavier
Collaborators: Guerrero Perez, Ana Isabel, Nos Llopis, Carlos, Malhotra Sareen, Sunny, Graells Salvador, José Ant., SGR-Cat 2021: Neuroimmunologia Clínica, Sastre Garriga, Jaume, Rio Izquierdo, Jordi, Galán Cartaña, Ingrid, Rosalia Horno Ocaña, Comabella Lopez, Manuel, Serrano Mascarós, Andrea, Capell Maymo, Margarida, Sánchez Pous, Samuel, Anglada Clofent, Elisenda, Cabello , Sergio, Tur Gomez, Carmen, SGR-Cat 2021: Neuroimmunologia Clínica, Eixarch Ahufinger, Herena, Santoyo Medina, Carme, Tintore Subirana, Mar, Arevalo Navines, M Jesus, Meza Murillo, Edwin Roger, Augusto Cesar Sao Aviles, Robles Sanchez, Miguel Angel, Muñoz Valdivielso, Dunia, Espejo Ruiz, Carmen, Filló Papiol, Nuria, Rodríguez Barranco, Marta, Loyola Sanmillan, Gaizka, Resina Salles, Mireia, Vidal Jordana, Angela, Gutiérrez Ruiz, Lucía, Zabalza de Torres, Ana, Vergara Ruiz, Sergio, Javier Villacieros Álvarez, Garcia Merida, Rafael, SGR-Cat 2021: Neuroimmunologia Clínica, Midaglia Fernandez, Luciana, Cobo Calvo, Alvaro, Mongay Ochoa, Neus, Castillo Justribo, Joaquin, Fraga Pereira, Milagros, Rodriguez Acevedo, Breogan, Miguez Gonzalez, Andres, SGR-Cat 2021: Neuroimmunologia Clínica, Castillo Juarez, Mireia, Pinteac , Rucsanda, Fissolo , Nicolás Miguel
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 31/12/2024

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: Malhotra Sareen, Sunny
Collaborators: Rio Izquierdo, Jordi, Zabalza de Torres, Ana, Pinteac , Rucsanda
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients

IP: Malhotra Sareen, Sunny
Collaborators: -
Funding agency: Fundación Merck Salud
Funding: 0.01
Reference: MERCK/PREM.SOLIDARIS/2020/MALHOTRA
Duration: 18/12/2020 - 18/12/2020

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple

IP: Comabella Lopez, Manuel
Collaborators: Malhotra Sareen, Sunny, Izquierdo Sans , Miriam
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 103807.4
Reference: SLT002/16/00357
Duration: 04/04/2017 - 31/12/2019

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Elizabeth Barba Orozco

Elizabeth Barba Orozco

Physiology and Pathophysiology of the Digestive Tract
Read more
Diana Bou Teen

Diana Bou Teen

Postdoctoral researcher
Cardiovascular Diseases
Read more
Stefan Huemmer

Stefan Huemmer

Main researcher
Translational Molecular Pathology
Read more
Carlos Alberto Piedra Calle

Carlos Alberto Piedra Calle

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.